BMJ

Purine-rich foods intake and recurrent gout attacks

1 Clinical Epidemiology Research and Training Unit, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA 2 Data Coordinating Center, Boston University School of ...
BMJ

Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group

20 Amsterdam Rheumatology & Immunology Center, Academic Medical Center, Amsterdam, The Netherlands Correspondence to Dr Robert G W Lambert, Department of Radiology and Diagnostic Imaging, University ...
BMJ

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

2 Rheumatology Department, Leiden University Medical Center, Leiden, The Netherlands 3 Rheumatology Department, Maastricht University Medical Center, Maastricht, The Netherlands Background The ...
BMJ

EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis

15 Department of Radiology. Leiden University Medical Centre, Leiden, The Netherlands 16 Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands ...
BMJ

AB1069 URIC ACID LEVELS IN RELATION TO FASTING BLOOD GLUCOSE AND HbA1c

2 Farhat Hached Hospital, Endocrinology and Diabetes Department, Sousse, Tunisia Background Hyperuricemia is reported to be a risk factor for the development of type 2 diabetes (T2D) and prediabetes.
BMJ

OP0039 ALPN-303, AN ENHANCED, POTENT DUAL BAFF/APRIL ANTAGONIST ENGINEERED BY DIRECTED EVOLUTION FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS ...

1 Alpine Immune Sciences, Translational Sciences, Seattle, United States of America 2 Alpine Immune Sciences Inc, Immunology, Seattle, United States of America 3 Alpine Immune Sciences Inc, Clinical ...
BMJ

POS1128 COMBINATION TREATMENT OF AR882, A NEW URAT1 INHIBITOR, AND XANTHINE OXIDASE INHIBITORS ALLOPURINOL OR FEBUXOSTAT: EFFECT ON URIC ACID ...

Background: Xanthine oxidase inhibitors (XOI) are commonly used as urate lowering therapy (ULT) for the treatment of gout. Allopurinol, the first-line treatment, demonstrates low response rate (< 40%) ...
BMJ

EULAR recommendations for the treatment of systemic sclerosis: 2023 update

Objectives To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. Methods An ...
BMJ

Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?

We read with great interest the recent paper by Aranow et al 1 about the impact of laboratory results on scoring of the Physician Global Assessment (PGA) of disease activity in systemic lupus ...
BMJ

OP0196 Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune diseases: a nationwide multicenter retrospective study

Background Immune Checkpoint Inhibitors (ICI) have revolutionised the management of several cancers, enhancing the anti-tumoral immune response. However they are responsible for many Immune Related ...
BMJ

CD-19 CAR-T cells for polyrefractory rheumatoid arthritis

‘Poly-refractory’ disease affects 2.7% of patients with rheumatoid arthritis (RA) who have failed different groups of biologic disease-modifying antirheumatic drugs (b-DMARDS) and targeted synthetic ...